Catalyst Pharma Patent Trial Against Hetero USA Delayed

Catalyst Pharma ( (CPRX) ) just unveiled an announcement.

On March 18, 2026, the District Court for the District of New Jersey postponed the start of Catalyst Pharmaceuticals’ bench trial against Hetero USA, Inc. from March 23, 2026, to May 18, 2026. The case centers on the validity of Catalyst’s Orange Book-listed patents covering its rare disease drug FIRDAPSE, which are set to expire in 2032, 2034, and 2037, potentially affecting the timing of generic competition and the durability of the company’s revenue from this key product.

The most recent analyst rating on (CPRX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

The score is driven primarily by strong financial performance (rapid revenue scaling, high profitability, low leverage, and solid cash generation) and a constructive earnings outlook supported by 2026 revenue guidance and strong product momentum. Technicals add support via an ongoing uptrend, while valuation appears reasonable on earnings but is tempered by no dividend and acknowledged business risks (FYCOMPA decline, litigation, and gross-to-net/cost pressures).

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Catalyst Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for rare neurological and neuromuscular diseases. Its portfolio includes FIRDAPSE, a treatment for patients with Lambert-Eaton myasthenic syndrome and related rare conditions in the U.S. market.

Average Trading Volume: 1,202,838

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2.85B

For an in-depth examination of CPRX stock, go to TipRanks’ Overview page.